Figure 1.

Study design schematic.¹A confirmatory refill within 30 days of both mirabegron and any antimuscarinic were required to verify that the first observed instance was a combination therapy (and not a treatment switch). If the antimuscarinic continues after discontinuation of mirabegron (or vice versa), this is considered a de‐escalation and new line of therapy. ²Simultaneous codes of revision or removal of peripheral neurostimulator electrode array and pulse generator or receiver OR one of these revision/removal codes with no follow‐up maintenance code for more than 6 months were considered sacral nerve stimulation discontinuation